var data={"title":"Protein-losing gastroenteropathy","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Protein-losing gastroenteropathy</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/contributors\" class=\"contributor contributor_credentials\">Vladan Milovic, MD, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/contributors\" class=\"contributor contributor_credentials\">Richard J Grand, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/contributors\" class=\"contributor contributor_credentials\">J Thomas Lamont, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/contributors\" class=\"contributor contributor_credentials\">Shilpa Grover, MD, MPH, AGAF</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 27, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Protein-losing gastroenteropathies are characterized by an excessive loss of serum proteins into the gastrointestinal tract, resulting in hypoproteinemia, edema, and, in some cases, pleural and pericardial effusions. The diagnosis of protein-losing gastroenteropathy should be considered in patients with hypoproteinemia in whom other causes, such as malnutrition, heavy proteinuria, and impaired protein synthesis, due to liver diseases, have been excluded.</p><p>This topic will review the etiology, pathogenesis, clinical manifestations, diagnosis and management of protein-losing gastroenteropathy. Other causes of hypoalbuminemia are discussed elsewhere. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-malabsorption#H18\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of malabsorption&quot;, section on 'Protein malabsorption'</a> and <a href=\"topic.htm?path=mechanisms-of-nutrient-absorption-and-malabsorption#H4\" class=\"medical medical_review\">&quot;Mechanisms of nutrient absorption and malabsorption&quot;, section on 'Protein absorption'</a> and <a href=\"topic.htm?path=overview-of-heavy-proteinuria-and-the-nephrotic-syndrome\" class=\"medical medical_review\">&quot;Overview of heavy proteinuria and the nephrotic syndrome&quot;</a> and <a href=\"topic.htm?path=tests-of-the-livers-biosynthetic-capacity-eg-albumin-coagulation-factors-prothrombin-time#H3\" class=\"medical medical_review\">&quot;Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)&quot;, section on 'Albumin'</a>.)</p><p class=\"headingAnchor\" id=\"H3413491955\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The normal gastrointestinal tract does not contribute significantly to the catabolism of plasma proteins, accounting for only about 10 percent of the normal turnover of albumin and gamma globulin [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/1\" class=\"abstract_t\">1</a>]. Once plasma proteins pass into the gastrointestinal tract, they are degraded rapidly to amino acids and reabsorbed into the portal circulation. </p><p>Protein-losing gastroenteropathy can be caused by a diverse group of disorders (<a href=\"image.htm?imageKey=GAST%2F53419\" class=\"graphic graphic_table graphicRef53419 \">table 1</a>). Intestinal leakage of plasma proteins occurs via one of the following mechanisms:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Inflammatory exudation</strong> &ndash; Mucosal injury results in exudation of protein-rich fluids across the eroded epithelium. The degree of mucosal involvement typically correlates with the severity of protein loss.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Increased mucosal permeability</strong> &ndash; Altered integrity of the mucosa of the stomach, small bowel, and colon results in protein leakage into the lumen.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Intestinal loss of lymphatic fluid</strong> &ndash; Lymphatic obstruction due to granulomatous or neoplastic involvement of the lymphatic system, congenital abnormalities of the lymphatic system, or disorders of venous stasis (eg, congestive heart failure or constrictive pericarditis) result in increased lymphatic pressure. The increased pressure in the lymphatics results in decreased absorption of chylomicrons and fat soluble vitamins (A, D, E, K), reduced recirculation of intestinal lymphocytes into the peripheral circulation and leakage of lymph into the intestinal lumen [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/2\" class=\"abstract_t\">2</a>].</p><p/><p>In patients with protein-losing gastroenteropathy, gastrointestinal leakage of serum proteins occurs independent of their molecular weight. In addition to albumin, other serum components that may also be lost in the gut include iron, lipids, and trace elements. Hypoproteinemia occurs if the extent of net enteral protein loss is greater than the capacity of liver to synthesize particular proteins. Hepatic protein synthesis in patients with protein-losing gastroenteropathy is usually normal or only slightly increased. Thus, gastrointestinal protein loss results in reduction of serum concentrations of proteins that have a slow catabolic rate (eg, albumin, IgA, IgG, IgM). By contrast, there is little change in the serum concentrations of proteins with a rapid turnover rate (eg, insulin, IgE). </p><p class=\"headingAnchor\" id=\"H776519286\"><span class=\"h1\">ETIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Protein-losing gastroenteropathies can be caused by a diverse group of disorders (<a href=\"image.htm?imageKey=GAST%2F53419\" class=\"graphic graphic_table graphicRef53419 \">table 1</a>). </p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Erosive gastrointestinal diseases</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Enteral protein loss in patients with inflammatory bowel disease (eg, ulcerative colitis and Crohn disease) and gastrointestinal malignancies results from inflammatory exudation and absorptive loss from mucosal erosions and ulcerations. In addition, both Crohn disease and malignancy can cause lymphatic obstruction in the mesentery, leading to increased lymphatic pressure and the leakage of lymph into the gut lumen [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/3\" class=\"abstract_t\">3</a>]. Protein-losing gastroenteropathy also occurs in a subset of patients with colitis due to Clostridium difficile infection but not in patients with asymptomatic colonization [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/4,5\" class=\"abstract_t\">4,5</a>]. (See <a href=\"topic.htm?path=clostridium-difficile-infection-in-adults-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Clostridium difficile infection in adults: Clinical manifestations and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Nonerosive gastrointestinal diseases</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of conditions can alter the integrity of the mucosa of the stomach, small bowel, or colon and cause protein leakage into the lumen (<a href=\"image.htm?imageKey=GAST%2F53419\" class=\"graphic graphic_table graphicRef53419 \">table 1</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Intestinal</strong> <strong>disease</strong> &mdash; Protein-losing gastroenteropathy in celiac disease and tropical sprue is a consequence of the loss of villous structures and surface epithelium that facilitate the diffusion of plasma proteins between the cells. Other conditions that can be associated with protein-losing gastroenteropathy include allergic gastroenteropathy, eosinophilic gastroenteritis, collagenous colitis, systemic lupus erythematosus, and carbohydrate-deficient glycoprotein syndrome [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/6-10\" class=\"abstract_t\">6-10</a>]. (See <a href=\"topic.htm?path=eosinophilic-gastroenteritis\" class=\"medical medical_review\">&quot;Eosinophilic gastroenteritis&quot;</a> and <a href=\"topic.htm?path=lymphocytic-and-collagenous-colitis-microscopic-colitis-clinical-manifestations-diagnosis-and-management\" class=\"medical medical_review\">&quot;Lymphocytic and collagenous colitis (microscopic colitis): Clinical manifestations, diagnosis, and management&quot;</a> and <a href=\"topic.htm?path=overview-of-the-clinical-manifestations-of-systemic-lupus-erythematosus-in-adults\" class=\"medical medical_review\">&quot;Overview of the clinical manifestations of systemic lupus erythematosus in adults&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Giant</strong> <strong>hypertrophic</strong> <strong>gastropathy</strong> &mdash; Several proliferative, inflammatory, and infiltrative conditions are associated with large or giant mucosal folds in the stomach and protein-losing gastroenteropathy. Of these, M&eacute;n&eacute;trier's disease, is the most common gastric disorder associated with gastrointestinal protein loss [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/11\" class=\"abstract_t\">11</a>]. Increased intracellular permeability and wider tight junctions between cells leads to protein-rich exudates in the stomach. Other gastric causes of protein-losing gastroenteropathy include <em>H. pylori </em>gastritis and lymphocytic gastritis [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/12-16\" class=\"abstract_t\">12-16</a>]. (See <a href=\"topic.htm?path=large-gastric-folds-hyperplastic-and-nonhyperplastic-gastropathies#H5\" class=\"medical medical_review\">&quot;Large gastric folds: Hyperplastic and nonhyperplastic gastropathies&quot;, section on 'M&eacute;n&eacute;trier's disease'</a> and <a href=\"topic.htm?path=large-gastric-folds-hyperplastic-and-nonhyperplastic-gastropathies#H12\" class=\"medical medical_review\">&quot;Large gastric folds: Hyperplastic and nonhyperplastic gastropathies&quot;, section on 'Large gastric folds associated with other conditions'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Amyloidosis</strong> &mdash; Patients with gastrointestinal amyloidosis can present with protein-losing gastroenteropathy due to mucosal infiltration [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/17\" class=\"abstract_t\">17</a>]. (See <a href=\"topic.htm?path=gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management#H6\" class=\"medical medical_review\">&quot;Gastrointestinal amyloidosis: Clinical manifestations, diagnosis, and management&quot;, section on 'Gastrointestinal tract amyloidosis'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Diseases with lymphatic obstruction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intestinal lymphangiectasia is characterized by impaired small intestinal lymph drainage associated with dilated intestinal lymphatic channels. It can be due to primary disorders of intestinal lymphatics or secondary to other causes (eg, right-sided heart failure) (<a href=\"image.htm?imageKey=GAST%2F53419\" class=\"graphic graphic_table graphicRef53419 \">table 1</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Primary</strong> <strong>intestinal</strong> <strong>lymphangiectasia</strong> &mdash; Primary intestinal lymphangiectasia is characterized by diffuse or localized ectasia of enteric lymphatics, which is often associated with lymphatic abnormalities elsewhere in the body [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/18\" class=\"abstract_t\">18</a>]. The ectatic lymphatics may be located in the mucosa, submucosa, or subserosa. In patients with lymphatic obstruction and particularly congenital lymphangiectasia, loss of lymphocytes into the gut can produce significant lymphocytopenia<strong> </strong>with detectable alterations in cellular immunity. </p><p/><p class=\"bulletIndent1\">The disease primarily affects children and young adults. The mean age of onset is approximately 11 years, but patients often have symptoms much earlier [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/18\" class=\"abstract_t\">18</a>]. Although most cases are sporadic, primary intestinal lymphangiectasia has been reported in multiple siblings of several families, suggesting that at least in certain cases it may have an underlying genetic cause. Biallelic loss of function mutations in <em>CD55 </em>which<em> </em>encodes decay-accelerating factor and thereby regulates the complement cascade, has been associated with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE syndrome) [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/19\" class=\"abstract_t\">19</a>]. Protein-losing gastroenteropathy has also been reported in association with the yellow-nail syndrome (triad of pulmonary disease, lymphedema, and slow-growing, yellow nails without a cuticle or lunula), Turner's syndrome, Noonan's syndrome, Hennekam, von Recklinghausen, and Klippel-Trenaunay syndrome [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/20\" class=\"abstract_t\">20</a>]. Several rare genetic syndromes have also been associated with protein-losing enteropathy. The pathogenesis in these cases is largely lymphatic obstruction leading to intestinal lymphangiectasia. The disorders include camptodactyly-arthopathy-coxa vara- pericarditis syndrome (mutations in PRG4, [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/21\" class=\"abstract_t\">21</a>]); protein-losing enteropathy with intestinal lymphangiectasia and skeletal dysplasia (mutations in FGFR3, [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/22\" class=\"abstract_t\">22</a>]); congenital protein-losing enteropathy with errors in lipid metabolism (mutations in DGAT1, [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/23\" class=\"abstract_t\">23</a>]); and plasmalemma vesicle-associated protein deficiency (mutation in PLVAP, [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/24\" class=\"abstract_t\">24</a>]) and tuberous sclerosis (mutation in TSC2, [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/25\" class=\"abstract_t\">25</a>]). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Secondary</strong> <strong>intestinal</strong> <strong>lymphangiectasia</strong> &mdash; The most common causes of secondary intestinal lymphangiectasia are cardiac diseases and retroperitoneal lymph node enlargement due to chemotherapeutic, infectious, or toxic substances (<a href=\"image.htm?imageKey=GAST%2F53419\" class=\"graphic graphic_table graphicRef53419 \">table 1</a>). Cardiac conditions that can lead to the development of secondary lymphangiectasia include structural heart disease (eg, tricuspid insufficiency, congenital pulmonic stenosis, and atrial septal defect), constrictive pericarditis, cardiomyopathy, and surgical repair of complex congenital heart disease (eg Fontan procedure for a functional single ventricle) [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/26-29\" class=\"abstract_t\">26-29</a>]. Secondary intestinal lymphangiectasia has also been described in patients with portal hypertension or hepatic venous outflow obstruction after liver transplantation, and in congenital hepatic fibrosis due to phosphomannose isomerase deficiency [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/30\" class=\"abstract_t\">30</a>]. (See <a href=\"topic.htm?path=management-of-patients-post-fontan-procedure#H108726786\" class=\"medical medical_review\">&quot;Management of patients post-Fontan procedure&quot;, section on 'Fontan &quot;physiology&quot;'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2821906469\"><span class=\"h1\">CLINICAL FEATURES</span></p><p class=\"headingAnchor\" id=\"H2613615109\"><span class=\"h2\">Clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical manifestations of protein-losing gastroenteropathy are highly variable and are determined by the underlying cause. Patients usually present with peripheral edema. Rarely patients may present with gradually progressive dyspnea or painless abdominal distention due to symptomatic pleural effusions or ascites. Gastrointestinal symptoms of diarrhea, steatorrhea, abdominal pain, bloating, or flatulence may be present in patients with underlying small bowel or colonic disease (<a href=\"image.htm?imageKey=GAST%2F53419\" class=\"graphic graphic_table graphicRef53419 \">table 1</a>). </p><p/><p>Patients with primary intestinal lymphangiectasia present in childhood with edema, weight loss, intermittent diarrhea, nausea, and vomiting. Some patients develop steatorrhea. Peripheral edema is often present and may be pitting if it results from hypoalbuminemia, or asymmetric and nonpitting if it results from an underlying lymphatic abnormality of the affected extremity. Reversible blindness can rarely occur due to macular edema. Chylothorax or chylous ascites may also be present. Hypogammaglobulinemia and lymphopenia are variable and some patients may develop frequent and opportunistic infections. (See <a href=\"topic.htm?path=diagnostic-evaluation-of-a-pleural-effusion-in-adults-initial-testing\" class=\"medical medical_review\">&quot;Diagnostic evaluation of a pleural effusion in adults: Initial testing&quot;</a> and <a href=\"topic.htm?path=etiology-clinical-presentation-and-diagnosis-of-chylothorax\" class=\"medical medical_review\">&quot;Etiology, clinical presentation, and diagnosis of chylothorax&quot;</a> and <a href=\"topic.htm?path=chylous-bloody-and-pancreatic-ascites#H1\" class=\"medical medical_review\">&quot;Chylous, bloody, and pancreatic ascites&quot;, section on 'Chylous ascites'</a>.)</p><p>Patients with protein-losing gastroenteropathy secondary to cardiac disease can have profound hypoproteinemia with clinically significant nutritional and immunologic consequences. Clinical features include edema, ascites, pleural, and pericardial effusions, failure to thrive, frequent infections and in some cases sepsis due to chronic hypogammaglobulinemia. Severe third-spacing of body fluids further compromises the already tenuous hemodynamics and intravascular volume loss. The combination of increased central venous pressures and low cardiac output places the patient at risk for thromboembolism. (See <a href=\"topic.htm?path=management-of-patients-post-fontan-procedure#H108726786\" class=\"medical medical_review\">&quot;Management of patients post-Fontan procedure&quot;, section on 'Fontan &quot;physiology&quot;'</a> and <a href=\"topic.htm?path=management-of-patients-post-fontan-procedure#H13723701\" class=\"medical medical_review\">&quot;Management of patients post-Fontan procedure&quot;, section on 'Thromboembolic events'</a>.)</p><p class=\"headingAnchor\" id=\"H2733801850\"><span class=\"h2\">Laboratory findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The main laboratory findings in protein-losing enteropathy are reduced serum concentrations of albumin, gamma globulins (IgA, IgG, IgM), fibrinogen, cholesterol, transferrin, and ceruloplasmin (<a href=\"image.htm?imageKey=GAST%2F65661\" class=\"graphic graphic_table graphicRef65661 \">table 2</a>). Patients may have fat soluble vitamin deficiencies due to their underlying small bowel disease (eg, celiac disease, Crohn disease). </p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Protein-losing gastroenteropathy should be suspected in patients with edema and hypoalbuminemia in whom there is no other apparent cause of protein loss (eg, proteinuria) or inadequate synthesis (eg, liver diseases) or supply (eg, protein malnutrition). The diagnosis of protein-losing gastroenteropathy is established by an increase in alpha-1 antitrypsin clearance. (See <a href=\"topic.htm?path=laboratory-and-radiologic-evaluation-of-nutritional-status-in-children\" class=\"medical medical_review\">&quot;Laboratory and radiologic evaluation of nutritional status in children&quot;</a> and <a href=\"topic.htm?path=failure-to-thrive-in-elderly-adults-evaluation\" class=\"medical medical_review\">&quot;Failure to thrive in elderly adults: Evaluation&quot;</a> and <a href=\"topic.htm?path=malnutrition-in-children-in-resource-limited-countries-clinical-assessment\" class=\"medical medical_review\">&quot;Malnutrition in children in resource-limited countries: Clinical assessment&quot;</a> and <a href=\"topic.htm?path=evaluation-of-proteinuria-in-children\" class=\"medical medical_review\">&quot;Evaluation of proteinuria in children&quot;</a> and <a href=\"topic.htm?path=assessment-of-urinary-protein-excretion-and-evaluation-of-isolated-non-nephrotic-proteinuria-in-adults\" class=\"medical medical_review\">&quot;Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults&quot;</a> and <a href=\"topic.htm?path=cirrhosis-in-adults-etiologies-clinical-manifestations-and-diagnosis#H71302286\" class=\"medical medical_review\">&quot;Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis&quot;, section on 'Diagnosis'</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-edema-in-adults\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of edema in adults&quot;</a> and <a href=\"topic.htm?path=evaluation-and-management-of-edema-in-children\" class=\"medical medical_review\">&quot;Evaluation and management of edema in children&quot;</a>.)</p><p>Alpha-1 antitrypsin is a glycoprotein synthesized in the liver and is the main component of the alpha-1 globulins. Alpha-l antitrypsin has a higher molecular weight than albumin and is excreted intact in the stool because it is resistant to proteolysis and degradation in the intestinal lumen [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/31,32\" class=\"abstract_t\">31,32</a>]. The normal rate of alpha-1 antitrypsin excretion in the stool is less than 2.6 <span class=\"nowrap\">mg/g</span> stool which reflects an intestinal clearance of less than 13 <span class=\"nowrap\">mL/day</span> [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/32,33\" class=\"abstract_t\">32,33</a>]. Elevated alpha-1-antitrypsin clearance suggests increased enteral protein loss. </p><p>The alpha 1-antitrypsin clearance test requires a 24-hour stool specimen and a serum sample for simultaneous measurement of alpha 1-antitrypsin in plasma.</p><p>Alpha 1-antitrypsin clearance = (stool volume) x (stool alpha <span class=\"nowrap\">1-antitrypsin)/</span> (serum alpha-1 antitrypsin)</p><p>Diarrhea, even in the absence of protein-losing gastroenteropathy, can increase clearance of alpha-1 antitrypsin from plasma [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/33\" class=\"abstract_t\">33</a>]. Alpha-1 antitrypsin clearance values indicative of protein-losing enteropathy are greater than 27 <span class=\"nowrap\">mL/24</span> hours in patients without diarrhea and greater than 56 <span class=\"nowrap\">mL/day</span> in patients with diarrhea.</p><p>Alpha-1 antitrypsin is degraded by gastric acid with a pH below 3.5, in patients with suspected hypertrophic secretory gastropathy or in those with apparent gastrointestinal protein loss but a normal alpha-1 antitrypsin clearance, alpha-1 antitrypsin clearance should be performed while the patient is on acid suppression (eg, <a href=\"topic.htm?path=omeprazole-drug-information\" class=\"drug drug_general\">omeprazole</a> 40 mg once daily) [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/32,34\" class=\"abstract_t\">32,34</a>].</p><p>Intestinal bleeding can significantly increase alpha-1 antitrypsin clearance rates [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/33\" class=\"abstract_t\">33</a>]. </p><p>Clearance of radiolabeled macromolecules (eg, 51Cr-labeled albumin, 125-I-labeled albumin, and 99mTc-labeled transferrin) is not routinely performed to diagnose protein-losing gastroenteropathy as alpha-1 antitrypsin clearance is less expensive and less cumbersome to perform. The sensitivity and specificity of alpha-1 antitrypsin clearance as compared with 51Cr-labeled albumin are 93 and 90<em> </em>percent, respectively [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/32\" class=\"abstract_t\">32</a>]. Fecal alpha 1-antitrypsin concentration is not a reliable test for protein-losing gastroenteropathy. There is poor correlation between random stool alpha-1 antitrypsin concentrations and alpha-1 antitrypsin clearance measurements [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/33\" class=\"abstract_t\">33</a>].</p><p class=\"headingAnchor\" id=\"H3915340355\"><span class=\"h1\">POST-DIAGNOSTIC EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The goal of the post-diagnostic evaluation in patients with protein-losing gastroenteropathy is to determine the underlying etiology.</p><p class=\"headingAnchor\" id=\"H706528998\"><span class=\"h2\">Our approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In most patients, the etiology can be established from the history, physical examination, and laboratory data (<a href=\"image.htm?imageKey=GAST%2F53419\" class=\"graphic graphic_table graphicRef53419 \">table 1</a>). The information gained from the initial evaluation will guide further testing. For example, patients with dyspnea on exertion should undergo echocardiography. (See <a href=\"#H1633370367\" class=\"local\">'Additional testing'</a> below.)</p><p>If patients have symptoms suggesting either an upper or lower GI etiology, it is reasonable to start the evaluation with an upper endoscopy or colonoscopy, respectively. If patients do not undergo both an upper endoscopy and colonoscopy initially and no lesion is identified during the initial examination that explains the protein-losing gastroenteropathy, the other test (either an upper endoscopy or colonoscopy) should be performed. If both upper endoscopy and colonoscopy are negative, abdominal imaging should be pursued. </p><p>For patients who are asymptomatic, we typically start with abdominal imaging to identify the underlying etiology. If the etiology is still not apparent, we perform endoscopic evaluation with both an upper endoscopy and colonoscopy. </p><p>We perform a video capsule endoscopy if the underlying etiology continues to remain uncertain or small bowel etiology is suspected. </p><p class=\"headingAnchor\" id=\"H1961290320\"><span class=\"h2\">History and physical examination</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The history should include the duration of symptoms and the presence of associated symptoms (eg, onset of edema in the hands and feet of a newborn girl is suggestive of Turner syndrome; the presence of shortness of breath may be due to heart failure or pleural effusion).</p><p>A history of risk factors for protein-losing gastroenteropathy should be sought. This includes a history of recent travel to areas endemic for parasitic infections, recent antibiotic use that might predispose to an infection with <em>Clostridium difficile,</em> chemotherapy, and NSAID exposure. Other important historical features include a history of inflammatory bowel disease, rheumatic disease (eg, systemic lupus erythematosus), gastrointestinal malignancy, or heart disease (<a href=\"image.htm?imageKey=GAST%2F53419\" class=\"graphic graphic_table graphicRef53419 \">table 1</a>). </p><p>Physical examination findings that may be suggestive of the underlying etiology include an elevated jugular venous pressure in a patient with right-sided heart failure. (See <a href=\"topic.htm?path=evaluation-of-the-patient-with-suspected-heart-failure\" class=\"medical medical_review\">&quot;Evaluation of the patient with suspected heart failure&quot;</a> and <a href=\"topic.htm?path=differentiating-constrictive-pericarditis-and-restrictive-cardiomyopathy\" class=\"medical medical_review\">&quot;Differentiating constrictive pericarditis and restrictive cardiomyopathy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3465370309\"><span class=\"h2\">Laboratory studies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Laboratory evaluation in patients with protein-losing gastroenteropathy should include a complete blood count with differential, serum chemistries including renal and liver function tests, and celiac serologies. Laboratory studies should also include stool examination for ova and parasites, stool <em>C. difficile</em> toxin and a <em>Giardia</em> stool antigen test, particularly if the patient has risk factors such as recent travel to endemic areas. In addition, serum albumin, serum retinol, 25-hydroxyvitamin D, alpha-tocopherol, PIVKA-II [proteins induced in vitamin K absence] should be obtained to assess the degree of hypoalbuminemia and to detect associated fat-soluble vitamin deficiencies. (See <a href=\"#H2733801850\" class=\"local\">'Laboratory findings'</a> above.)</p><p class=\"headingAnchor\" id=\"H142943003\"><span class=\"h2\">Abdominal imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Computed tomography scan or magnetic resonance imaging of the abdomen may demonstrate lymphadenopathy suggestive of lymphoma, mesenteric panniculitis suggestive of sclerosing mesenteritis, and thickening of the bowel wall suggestive of inflammatory bowel disease or infectious colitis. In patients with primary intestinal lymphangiectasia, mucosal folds appear thickened and nodular simulating stacked coins [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/35\" class=\"abstract_t\">35</a>]. (See <a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-non-hodgkin-lymphoma#H17\" class=\"medical medical_review\">&quot;Clinical presentation and diagnosis of non-Hodgkin lymphoma&quot;, section on 'Abdomen and pelvis'</a> and <a href=\"topic.htm?path=sclerosing-mesenteritis\" class=\"medical medical_review\">&quot;Sclerosing mesenteritis&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-ulcerative-colitis-in-adults#H1844648373\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults&quot;, section on 'Imaging'</a> and <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-crohn-disease-in-adults#H12689169\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis and prognosis of Crohn disease in adults&quot;, section on 'Imaging studies'</a> and <a href=\"topic.htm?path=clostridium-difficile-infection-in-adults-clinical-manifestations-and-diagnosis#H7229445\" class=\"medical medical_review\">&quot;Clostridium difficile infection in adults: Clinical manifestations and diagnosis&quot;, section on 'Radiographic imaging'</a>.)</p><p class=\"headingAnchor\" id=\"H1516970064\"><span class=\"h2\">Endoscopy and biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with hyperplastic gastropathies (eg, M&eacute;n&eacute;trier's disease, hyperplastic hypersecretory gastropathy, and Zollinger-Ellison syndrome) have enlarged gastric folds or rugae on endoscopy. Patients with Zollinger-Ellison syndrome may have multiple peptic ulcers. (See <a href=\"topic.htm?path=large-gastric-folds-hyperplastic-and-nonhyperplastic-gastropathies#H5\" class=\"medical medical_review\">&quot;Large gastric folds: Hyperplastic and nonhyperplastic gastropathies&quot;, section on 'M&eacute;n&eacute;trier's disease'</a> and <a href=\"topic.htm?path=zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis#H17088667\" class=\"medical medical_review\">&quot;Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis&quot;, section on 'Endoscopic features'</a>.)</p><p>In patients with primary intestinal lymphangiectasia, scattered white spots (snowflake-like appearance) overlie the small intestinal mucosa [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/36,37\" class=\"abstract_t\">36,37</a>]. Consumption of a high-fat meal the evening before endoscopic evaluation can make these findings more apparent. Histopathologic examination reveals markedly dilated lymphatics that are most apparent in the tips of the villi. In addition, electron microscopy reveals dilated lymphatic vessels filled with chylomicrons and precipitated lymph proteins. These findings are also present in the dilated intraepithelial gaps extending from the basolateral membrane to the apical region of the epithelium.</p><p class=\"bulletIndent1\">Endoscopic findings in patients with inflammatory bowel disease and microscopic colitis are nonspecific, and biopsies of the colon are necessary to establish the diagnosis and rule out other causes of colitis. Histopathological findings in patients with inflammatory bowel disease and microscopic colitis are discussed in detail separately. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-ulcerative-colitis-in-adults#H596557081\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults&quot;, section on 'Endoscopy and biopsy'</a> and <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-crohn-disease-in-adults#H2893457\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis and prognosis of Crohn disease in adults&quot;, section on 'Endoscopy'</a> and <a href=\"topic.htm?path=lymphocytic-and-collagenous-colitis-microscopic-colitis-clinical-manifestations-diagnosis-and-management#H973560197\" class=\"medical medical_review\">&quot;Lymphocytic and collagenous colitis (microscopic colitis): Clinical manifestations, diagnosis, and management&quot;, section on 'Endoscopy and biopsy'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1633370367\"><span class=\"h2\">Additional testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Additional testing should be guided by the signs and symptoms and results of prior evaluation. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Autoantibody testing and related studies</strong> &ndash; In patients with features in their medical history, physical examination, or other testing (eg, serum creatinine) that suggests a possible systemic rheumatic disorder, we obtain serologic and other studies based upon the specific condition suspected from the features that are present.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Cardiac echocardiogram</strong> &ndash; In patients with clinical suspicion of cardiac involvement, such as signs or symptoms of heart failure, we obtain an echocardiogram.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Other imaging techniques </strong>&ndash; In patients with intestinal lymphangiectasia, abnormal intestinal lymphatics can also be demonstrated by contrast lymphangiography, nuclear scintigraphy, or magnetic resonance lymphangiography [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/38-40\" class=\"abstract_t\">38-40</a>]. However, these tests offer little additional information once an alpha-1 antitrypsin clearance test has been performed and the value of these techniques in routine clinical practice is not established. Contrast lymphangiography involving injection of contrast material via the pedal vein is painful and of low sensitivity. Nuclear scintigraphy has been reported to demonstrate the abnormal intestinal lymphatics by using a technetium labeled tracer (usually albumin or dextran) and assessing intestinal leakage [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/39,40\" class=\"abstract_t\">39,40</a>]. </p><p/><p class=\"headingAnchor\" id=\"H2627810906\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of protein-losing gastroenteropathy is broad and varies based on the clinical presentation. The differential diagnosis of hypoalbuminemia and edema includes renal disease with proteinuria, liver diseases leading to inadequate protein synthesis, and protein malnutrition. (See <a href=\"topic.htm?path=pathophysiology-and-etiology-of-edema-in-adults\" class=\"medical medical_review\">&quot;Pathophysiology and etiology of edema in adults&quot;</a> and <a href=\"topic.htm?path=overview-of-heavy-proteinuria-and-the-nephrotic-syndrome\" class=\"medical medical_review\">&quot;Overview of heavy proteinuria and the nephrotic syndrome&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Management of protein-losing gastroenteropathy consists of two components:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dietary therapy to improve nutrition </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment of the underlying disease</p><p/><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Dietary therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The mainstay of dietary therapy is a low-fat, high-protein, medium-chain triglyceride (MCT) diet. This approach is associated with favorable effects on hypoalbuminemia, gastrointestinal symptoms, and growth [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/35,41,42\" class=\"abstract_t\">35,41,42</a>]. Patients should be encouraged to work closely with an experienced dietician. </p><p>The diet in patients with protein-losing gastroenteropathy should be low in long-chain fatty acids, generally present as long-chain triglycerides (LCTs). MCTs should be used to replace lipid calories. MCTs contain saturated fatty acids of 6 to 12 carbon atoms and are not re-esterified within the intestinal cell. MCTs bypass the enteric lymphatics and directly enter the portal system. It is believed that the reduction in intake of LCTs reduces lymphatic flow and pressure and decreases the quantity of lymph leakage. Various preparations of MCTs are commercially available; many contain caprylic acid (C8), capric acid (C10), and lauric acid (C12), and small amounts of fatty acids shorter than C8 and longer than C10. </p><p>The diet should also provide adequate supplies of essential polyunsaturated fatty acids. These are available in highest concentrations in flax seeds, walnuts, salmon, sardines, and soybeans, as well as in corn, canola, and safflower oils. In patients with fat-soluble vitamin deficiency these vitamins should be supplemented in water miscible or water soluble forms. (See <a href=\"topic.htm?path=overview-of-the-treatment-of-malabsorption#H5\" class=\"medical medical_review\">&quot;Overview of the treatment of malabsorption&quot;, section on 'Additional dietary principles'</a>.)</p><p>Protein requirements are increased in patients with protein-losing enteropathy to 1.5 to 3.0 <span class=\"nowrap\">g/kg</span> ideal body <span class=\"nowrap\">weight/day</span> in adults and 3 <span class=\"nowrap\">g/kg</span> ideal body weight per day in children and adolescents [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/43,44\" class=\"abstract_t\">43,44</a>]. The diet can be supplemented by commercially available protein formulas. Isolated protein supplements (eg, Casec, ProMod) are a reliable source of fat-free dietary protein, but are expensive and may be unpalatable. Supplements that provide both protein and nonprotein calories (eg, Ensure, Isocal, Peptamen, and PediaSure) may be more palatable. Whey protein supplements can be added to skim milk or starchy foods to increase protein intake. </p><p>Serum protein levels (albumin, immunoglobulins, transferrin, alpha 1-antitrypsin) should be monitored regularly, and protein intake should be adjusted to bring these values as close to normal as possible. The percentage of patients in whom hypoalbuminemia can be corrected varies considerably and depends upon the type and severity of the underlying disease. In patients with severe erosive disease or intestinal dysmotility, when protein requirements can only be partially met by oral feeding and oral supplements, additional calories and protein can be delivered parenterally. (See <a href=\"topic.htm?path=nutrition-support-in-critically-ill-patients-an-overview#H12\" class=\"medical medical_review\">&quot;Nutrition support in critically ill patients: An overview&quot;, section on 'Nutritional requirements'</a>.)</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Treatment of the underlying disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of the underlying disease has been associated with regression of protein-losing enteropathy. As examples, immunosuppressive therapy in patients with inflammatory diseases (eg, systemic lupus erythematosus, inflammatory bowel disease, gut graft versus host disease), pericardiectomy in patients with constrictive pericarditis, and repair of cardiac abnormalities and hepatic venous outflow obstruction [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/7,45-50\" class=\"abstract_t\">7,45-50</a>]. The treatments used for specific disorders are described in detail separately. (See <a href=\"topic.htm?path=large-gastric-folds-hyperplastic-and-nonhyperplastic-gastropathies#H9\" class=\"medical medical_review\">&quot;Large gastric folds: Hyperplastic and nonhyperplastic gastropathies&quot;, section on 'Treatment'</a> and <a href=\"topic.htm?path=management-of-patients-post-fontan-procedure#H13723709\" class=\"medical medical_review\">&quot;Management of patients post-Fontan procedure&quot;, section on 'Protein-losing enteropathy'</a> and <a href=\"topic.htm?path=constrictive-pericarditis#H21\" class=\"medical medical_review\">&quot;Constrictive pericarditis&quot;, section on 'Chronic constrictive pericarditis'</a>.)</p><p>Surgery (eg, intestinal resection or anastomosis of abnormal lymphatics to venous channels) should be reserved for patients with localized and refractory intestinal disease [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/35,51\" class=\"abstract_t\">35,51</a>]. However, these approaches are not always feasible. Patients with primary intestinal lymphangiectasia often have extensive lymphatic involvement precluding resection. Furthermore, focal lymphatic abnormalities are often difficult to localize. </p><p>Somatostatin analogue, <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a>, has been associated with an improvement in protein-losing gastroenteropathy in case reports of patients with Menetrier&rsquo;s disease (100 micrograms twice daily) and primary intestinal lymphangiectasia (200 micrograms twice daily) [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/52,53\" class=\"abstract_t\">52,53</a>]. However, there is insufficient evidence to routinely support its use. The mechanism by which octreotide decreases protein-losing enteropathy is unclear but likely relates to the reduction in splanchnic blood flow and reduced lymphatic pressure.</p><p>In a case report, three patients in a family with CHAPLE syndrome were treated with <a href=\"topic.htm?path=eculizumab-drug-information\" class=\"drug drug_general\">eculizumab</a>, a humanized monoclonal antibody to C5 [<a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/54\" class=\"abstract_t\">54</a>]. Within 100 days of initiation of therapy there was a significant reduction in complement activation, an increase in serum albumin and total protein concentrations, and an improvement in diarrhea. While these data suggest the importance of complement activation in a subset of patients with protein-losing enteropathy, the role of complement blockade in the treatment of protein-losing gastroenteropathy is unclear. (See <a href=\"#H10\" class=\"local\">'Diseases with lymphatic obstruction'</a> above.)</p><p class=\"headingAnchor\" id=\"H62464130\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Protein-losing gastroenteropathies are characterized by an excessive loss of serum proteins into the gastrointestinal tract. Protein-losing gastroenteropathies can be caused by a diverse group of disorders (<a href=\"image.htm?imageKey=GAST%2F53419\" class=\"graphic graphic_table graphicRef53419 \">table 1</a>). (See <a href=\"#H776519286\" class=\"local\">'Etiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intestinal leakage of plasma proteins results from inflammatory exudation due to mucosal injury; increased mucosal permeability due to altered integrity of the mucosa of the stomach, small bowel, and colon; and increased lymphatic pressure in the gut. (See <a href=\"#H3413491955\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The clinical manifestations of protein-losing gastroenteropathy are highly variable and are determined in part by the underlying cause (<a href=\"image.htm?imageKey=GAST%2F65661\" class=\"graphic graphic_table graphicRef65661 \">table 2</a>). Patients usually present with peripheral edema. Rarely patients may present with gradually progressive dyspnea or painless abdominal distention due to symptomatic pleural effusions or ascites. Gastrointestinal symptoms of diarrhea, steatorrhea, abdominal pain, bloating, or flatulence may be present in patients with underlying small bowel or colonic disease. (See <a href=\"#H2613615109\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The main laboratory findings in protein-losing enteropathy are reduced serum concentrations of albumin, gamma globulins (IgA, IgG, IgM), fibrinogen, cholesterol, transferrin, and ceruloplasmin. Patients may have fat-soluble vitamin deficiencies due to their underlying small bowel disease. (See <a href=\"#H2733801850\" class=\"local\">'Laboratory findings'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Protein-losing gastroenteropathy should be suspected in patients with edema and hypoalbuminemia in whom there is no other apparent cause of protein loss (eg, proteinuria) or inadequate synthesis (eg, liver diseases) or supply (eg, protein malnutrition). The diagnosis of protein-losing gastroenteropathy is established by an increase in alpha-1 antitrypsin clearance. (See <a href=\"#H17\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Once the diagnosis of protein-losing gastroenteropathy is established, the underlying etiology should be determined. In most patients, the diagnosis can be established from the history, physical examination, and laboratory data. The information gained from the initial evaluation will guide further testing. (See <a href=\"#H3915340355\" class=\"local\">'Post-diagnostic evaluation'</a> above and <a href=\"#H706528998\" class=\"local\">'Our approach'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Management of protein-losing gastroenteropathy consists of dietary therapy to improve nutrition and treatment the underlying disease. The mainstay of dietary therapy is a low-fat, high-protein, medium-chain triglyceride diet. (See <a href=\"#H18\" class=\"local\">'Management'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/1\" class=\"nounderline abstract_t\">Schmidt PN, Blirup-Jensen S, Svendsen PJ, Wandall JH. Characterization and quantification of plasma proteins excreted in faeces from healthy humans. Scand J Clin Lab Invest 1995; 55:35.</a></li><li class=\"breakAll\">Davidson NO. Intestinal lipid absorption. In: Textbook of Gastroenterology, Yamada T, Alpers DH, Kaplowitz N (Eds), JB Lippincott, Philadelphia 2003. p.413.</li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/3\" class=\"nounderline abstract_t\">Acciuffi S, Ghosh S, Ferguson A. Strengths and limitations of the Crohn's disease activity index, revealed by an objective gut lavage test of gastrointestinal protein loss. Aliment Pharmacol Ther 1996; 10:321.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/4\" class=\"nounderline abstract_t\">Rybolt AH, Bennett RG, Laughon BE, et al. Protein-losing enteropathy associated with Clostridium difficile infection. Lancet 1989; 1:1353.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/5\" class=\"nounderline abstract_t\">Dansinger ML, Johnson S, Jansen PC, et al. Protein-losing enteropathy is associated with Clostridium difficile diarrhea but not with asymptomatic colonization: a prospective, case-control study. Clin Infect Dis 1996; 22:932.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/6\" class=\"nounderline abstract_t\">Stark ME, Batts KP, Alexander GL. Protein-losing enteropathy with collagenous colitis. Am J Gastroenterol 1992; 87:780.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/7\" class=\"nounderline abstract_t\">Ebert EC, Hagspiel KD. Gastrointestinal and hepatic manifestations of systemic lupus erythematosus. J Clin Gastroenterol 2011; 45:436.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/8\" class=\"nounderline abstract_t\">Molina JF, Brown RF, Gedalia A, Espinoza LR. Protein losing enteropathy as the initial manifestation of childhood systemic lupus erythematosus. J Rheumatol 1996; 23:1269.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/9\" class=\"nounderline abstract_t\">Jaeken J, Vanderschueren-Lodeweyckx M, Casaer P. Familial psychomotor retardation with markedly fluctuating serum prolactin, FSH and GH levels, partial TBG-deficiency, increased serum arylsulfatase A and increased CSF protein: a new syndrome. Pediatr Res 1980; 14:179.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/10\" class=\"nounderline abstract_t\">Hendriksz CJ, McClean P, Henderson MJ, et al. Successful treatment of carbohydrate deficient glycoprotein syndrome type 1b with oral mannose. Arch Dis Child 2001; 85:339.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/11\" class=\"nounderline abstract_t\">Kelly DG, Miller LJ, Malagelada JR, et al. Giant hypertrophic gastropathy (M&eacute;n&eacute;trier's disease): pharmacologic effects on protein leakage and mucosal ultrastructure. Gastroenterology 1982; 83:581.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/12\" class=\"nounderline abstract_t\">Bayerd&ouml;rffer E, Ritter MM, Hatz R, et al. Healing of protein losing hypertrophic gastropathy by eradication of Helicobacter pylori--is Helicobacter pylori a pathogenic factor in M&eacute;n&eacute;trier's disease? Gut 1994; 35:701.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/13\" class=\"nounderline abstract_t\">Groisman GM, George J, Berman D, Harpaz N. Resolution of protein-losing hypertrophic lymphocytic gastritis with therapeutic eradication of Helicobacter pylori. Am J Gastroenterol 1994; 89:1548.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/14\" class=\"nounderline abstract_t\">Yamada M, Sumazaki R, Adachi H, et al. Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter pylori. Eur J Pediatr 1997; 156:182.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/15\" class=\"nounderline abstract_t\">Farahat K, Hainaut P, Jamar F, et al. Lymphocytic gastritis: an unusual cause of hypoproteinaemia. J Intern Med 1993; 234:95.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/16\" class=\"nounderline abstract_t\">Wolber RA, Owen DA, Anderson FH, Freeman HJ. Lymphocytic gastritis and giant gastric folds associated with gastrointestinal protein loss. Mod Pathol 1991; 4:13.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/17\" class=\"nounderline abstract_t\">Suzuki C, Higaki S, Nishiaki M, et al. 99mTc-HSA-D scintigraphy in the diagnosis of protein-losing gastroenteropathy due to secondary amyloidosis. J Gastroenterol 1997; 32:78.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/18\" class=\"nounderline abstract_t\">Umar SB, DiBaise JK. Protein-losing enteropathy: case illustrations and clinical review. Am J Gastroenterol 2010; 105:43.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/19\" class=\"nounderline abstract_t\">Ozen A, Comrie WA, Ardy RC, et al. CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis. N Engl J Med 2017; 377:52.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/20\" class=\"nounderline abstract_t\">Malek NP, Ocran K, Tietge UJ, et al. A case of the yellow nail syndrome associated with massive chylous ascites, pleural and pericardial effusions. Z Gastroenterol 1996; 34:763.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/21\" class=\"nounderline abstract_t\">Peters B, Schuurs-Hoeijmakers JH, Fuijkschot J, et al. Protein-losing enteropathy in camptodactyly-arthropathy-coxa vara-pericarditis (CACP) syndrome. Pediatr Rheumatol Online J 2016; 14:32.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/22\" class=\"nounderline abstract_t\">Yang C, Dehner LP. Protein-losing enteropathy with intestinal lymphangiectasia in skeletal dysplasia with Lys650Met mutation. Am J Med Genet A 2016; 170:2993.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/23\" class=\"nounderline abstract_t\">Stephen J, Vilboux T, Haberman Y, et al. Congenital protein losing enteropathy: an inborn error of lipid metabolism due to DGAT1 mutations. Eur J Hum Genet 2016; 24:1268.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/24\" class=\"nounderline abstract_t\">Elkadri A, Thoeni C, Deharvengt SJ, et al. Mutations in Plasmalemma Vesicle Associated Protein Result in Sieving Protein-Losing Enteropathy Characterized by Hypoproteinemia, Hypoalbuminemia, and Hypertriglyceridemia. Cell Mol Gastroenterol Hepatol 2015; 1:381.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/25\" class=\"nounderline abstract_t\">Pollack SF, Geffrey AL, Thiele EA, Shah U. Primary intestinal lymphangiectasia treated with rapamycin in a child with tuberous sclerosis complex (TSC). Am J Med Genet A 2015; 167A:2209.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/26\" class=\"nounderline abstract_t\">Meadows J, Jenkins K. Protein-losing enteropathy: integrating a new disease paradigm into recommendations for prevention and treatment. Cardiol Young 2011; 21:363.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/27\" class=\"nounderline abstract_t\">M&uuml;ller C, Globits S, Glogar D, et al. Constrictive pericarditis without typical haemodynamic changes as a cause of oedema formation due to protein-losing enteropathy. Eur Heart J 1991; 12:1140.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/28\" class=\"nounderline abstract_t\">Wilkinson P, Pinto B, Senior JR. Reversible protein-losing enteropathy with intestinal lymphangiectasia secondary to chronic constrictive pericarditis. N Engl J Med 1965; 273:1178.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/29\" class=\"nounderline abstract_t\">Feldt RH, Driscoll DJ, Offord KP, et al. Protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg 1996; 112:672.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/30\" class=\"nounderline abstract_t\">de Koning TJ, Dorland L, van Berge Henegouwen GP. Phosphomannose isomerase deficiency as a cause of congenital hepatic fibrosis and protein-losing enteropathy. J Hepatol 1999; 31:557.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/31\" class=\"nounderline abstract_t\">Bernier JJ, Florent C, Desmazures C, et al. Diagnosis of protein-losing enteropathy by gastrointestinal clearance of alpha1-antitrypsin. Lancet 1978; 2:763.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/32\" class=\"nounderline abstract_t\">Florent C, L'Hirondel C, Desmazures C, et al. Intestinal clearance of alpha 1-antitrypsin. A sensitive method for the detection of protein-losing enteropathy. Gastroenterology 1981; 81:777.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/33\" class=\"nounderline abstract_t\">Strygler B, Nicar MJ, Santangelo WC, et al. Alpha 1-antitrypsin excretion in stool in normal subjects and in patients with gastrointestinal disorders. Gastroenterology 1990; 99:1380.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/34\" class=\"nounderline abstract_t\">Florent C, Vidon N, Flouri&eacute; B, et al. Gastric clearance of alpha-1-antitrypsin under cimetidine perfusion. New test to detect protein-losing gastropathy? Dig Dis Sci 1986; 31:12.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/35\" class=\"nounderline abstract_t\">Vardy PA, Lebenthal E, Shwachman H. Intestinal lymphagiectasia: a reappraisal. Pediatrics 1975; 55:842.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/36\" class=\"nounderline abstract_t\">Freeman HJ, Nimmo M. Intestinal lymphangiectasia in adults. World J Gastrointest Oncol 2011; 3:19.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/37\" class=\"nounderline abstract_t\">Abramowsky C, Hupertz V, Kilbridge P, Czinn S. Intestinal lymphangiectasia in children: a study of upper gastrointestinal endoscopic biopsies. Pediatr Pathol 1989; 9:289.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/38\" class=\"nounderline abstract_t\">Laor T, Hoffer FA, Burrows PE, Kozakewich HP. MR lymphangiography in infants, children, and young adults. AJR Am J Roentgenol 1998; 171:1111.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/39\" class=\"nounderline abstract_t\">Yueh TC, Pui MH, Zeng SQ. Intestinal lymphangiectasia: value of Tc-99m dextran lymphoscintigraphy. Clin Nucl Med 1997; 22:695.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/40\" class=\"nounderline abstract_t\">Bhatnagar A, Lahoti D, Singh AK, et al. Scintigraphic diagnosis of protein losing enteropathy using Tc-99m dextran. Clin Nucl Med 1995; 20:1070.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/41\" class=\"nounderline abstract_t\">JEFFRIES GH, CHAPMAN A, SLEISENGER MH. LOW-FAT DIET IN INTESTINAL LYMPHANGIECTASIA. ITS EFFECT ON ALBUMIN METABOLISM. N Engl J Med 1964; 270:761.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/42\" class=\"nounderline abstract_t\">Tift WL, Lloyd JK. Intestinal lymphangiectasia. Long-term results with MCT diet. Arch Dis Child 1975; 50:269.</a></li><li class=\"breakAll\">Heimburger DC, Weinsier RL. Therapeutic diets. In: Handbook of Clinical Nutrition, 3rd ed, Heimburger DC, Weinsier RL (Eds), Mosby, St. Louis 1997. p.235.</li><li class=\"breakAll\">Alpers DH, Stenson WF, Bier DM. Nutritional planning for patients with protein and calorie deficiency. In: Manual of Nutritional Therapeutics, 3rd ed, Alpers DH, Stenson WF, Bier DM (Eds), Little, Brown, and Co., Boston, MA 1995. p.265.</li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/45\" class=\"nounderline abstract_t\">Jacobs ML, Rychik J, Byrum CJ, Norwood WI Jr. Protein-losing enteropathy after Fontan operation: resolution after baffle fenestration. Ann Thorac Surg 1996; 61:206.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/46\" class=\"nounderline abstract_t\">Donnelly JP, Rosenthal A, Castle VP, Holmes RD. Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation. J Pediatr 1997; 130:474.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/47\" class=\"nounderline abstract_t\">Masetti P, Marianeschi SM, Cipriani A, et al. Reversal of protein-losing enteropathy after ligation of systemic-pulmonary shunt. Ann Thorac Surg 1999; 67:235.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/48\" class=\"nounderline abstract_t\">Dousset B, Legmann P, Soubrane O, et al. Protein-losing enteropathy secondary to hepatic venous outflow obstruction after liver transplantation. J Hepatol 1997; 27:206.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/49\" class=\"nounderline abstract_t\">Stanley AJ, Gilmour HM, Ghosh S, et al. Transjugular intrahepatic portosystemic shunt as a treatment for protein-losing enteropathy caused by portal hypertension. Gastroenterology 1996; 111:1679.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/50\" class=\"nounderline abstract_t\">Sunagawa T, Kinjo F, Gakiya I, et al. Successful long-term treatment with cyclosporin A in protein losing gastroenteropathy. Intern Med 2004; 43:397.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/51\" class=\"nounderline abstract_t\">Mistilis SP, Skyring AP. Intestinal lymphangiectasia: Therapeutic effect of lymph venous anastomosis. Am J Med 1966; 40:634.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/52\" class=\"nounderline abstract_t\">Yeaton P, Frierson HF Jr. Octreotide reduces enteral protein losses in M&eacute;n&eacute;trier's disease. Am J Gastroenterol 1993; 88:95.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/53\" class=\"nounderline abstract_t\">Ballinger AB, Farthing MJ. Octreotide in the treatment of intestinal lymphangiectasia. Eur J Gastroenterol Hepatol 1998; 10:699.</a></li><li><a href=\"https://www.uptodate.com/contents/protein-losing-gastroenteropathy/abstract/54\" class=\"nounderline abstract_t\">Kurolap A, Eshach-Adiv O, Hershkovitz T, et al. Loss of CD55 in Eculizumab-Responsive Protein-Losing Enteropathy. N Engl J Med 2017; 377:87.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4769 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H62464130\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H3413491955\" id=\"outline-link-H3413491955\">PATHOGENESIS</a></li><li><a href=\"#H776519286\" id=\"outline-link-H776519286\">ETIOLOGY</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Erosive gastrointestinal diseases</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Nonerosive gastrointestinal diseases</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Diseases with lymphatic obstruction</a></li></ul></li><li><a href=\"#H2821906469\" id=\"outline-link-H2821906469\">CLINICAL FEATURES</a><ul><li><a href=\"#H2613615109\" id=\"outline-link-H2613615109\">Clinical manifestations</a></li><li><a href=\"#H2733801850\" id=\"outline-link-H2733801850\">Laboratory findings</a></li></ul></li><li><a href=\"#H17\" id=\"outline-link-H17\">DIAGNOSIS</a></li><li><a href=\"#H3915340355\" id=\"outline-link-H3915340355\">POST-DIAGNOSTIC EVALUATION</a><ul><li><a href=\"#H706528998\" id=\"outline-link-H706528998\">Our approach</a></li><li><a href=\"#H1961290320\" id=\"outline-link-H1961290320\">History and physical examination</a></li><li><a href=\"#H3465370309\" id=\"outline-link-H3465370309\">Laboratory studies</a></li><li><a href=\"#H142943003\" id=\"outline-link-H142943003\">Abdominal imaging</a></li><li><a href=\"#H1516970064\" id=\"outline-link-H1516970064\">Endoscopy and biopsy</a></li><li><a href=\"#H1633370367\" id=\"outline-link-H1633370367\">Additional testing</a></li></ul></li><li><a href=\"#H2627810906\" id=\"outline-link-H2627810906\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">MANAGEMENT</a><ul><li><a href=\"#H19\" id=\"outline-link-H19\">Dietary therapy</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">Treatment of the underlying disease</a></li></ul></li><li><a href=\"#H62464130\" id=\"outline-link-H62464130\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/4769|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/53419\" class=\"graphic graphic_table\">- Causes of protein-losing gastroenteropathy</a></li><li><a href=\"image.htm?imageKey=GAST/65661\" class=\"graphic graphic_table\">- Lab findings protein-losing gastroenteropathy</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=assessment-of-urinary-protein-excretion-and-evaluation-of-isolated-non-nephrotic-proteinuria-in-adults\" class=\"medical medical_review\">Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chylous-bloody-and-pancreatic-ascites\" class=\"medical medical_review\">Chylous, bloody, and pancreatic ascites</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cirrhosis-in-adults-etiologies-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-malabsorption\" class=\"medical medical_review\">Clinical features and diagnosis of malabsorption</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-edema-in-adults\" class=\"medical medical_review\">Clinical manifestations and diagnosis of edema in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-crohn-disease-in-adults\" class=\"medical medical_review\">Clinical manifestations, diagnosis and prognosis of Crohn disease in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-ulcerative-colitis-in-adults\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-non-hodgkin-lymphoma\" class=\"medical medical_review\">Clinical presentation and diagnosis of non-Hodgkin lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clostridium-difficile-infection-in-adults-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Clostridium difficile infection in adults: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=constrictive-pericarditis\" class=\"medical medical_review\">Constrictive pericarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-evaluation-of-a-pleural-effusion-in-adults-initial-testing\" class=\"medical medical_review\">Diagnostic evaluation of a pleural effusion in adults: Initial testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=differentiating-constrictive-pericarditis-and-restrictive-cardiomyopathy\" class=\"medical medical_review\">Differentiating constrictive pericarditis and restrictive cardiomyopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=eosinophilic-gastroenteritis\" class=\"medical medical_review\">Eosinophilic gastroenteritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=etiology-clinical-presentation-and-diagnosis-of-chylothorax\" class=\"medical medical_review\">Etiology, clinical presentation, and diagnosis of chylothorax</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-and-management-of-edema-in-children\" class=\"medical medical_review\">Evaluation and management of edema in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-proteinuria-in-children\" class=\"medical medical_review\">Evaluation of proteinuria in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-the-patient-with-suspected-heart-failure\" class=\"medical medical_review\">Evaluation of the patient with suspected heart failure</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=failure-to-thrive-in-elderly-adults-evaluation\" class=\"medical medical_review\">Failure to thrive in elderly adults: Evaluation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management\" class=\"medical medical_review\">Gastrointestinal amyloidosis: Clinical manifestations, diagnosis, and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=laboratory-and-radiologic-evaluation-of-nutritional-status-in-children\" class=\"medical medical_review\">Laboratory and radiologic evaluation of nutritional status in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=large-gastric-folds-hyperplastic-and-nonhyperplastic-gastropathies\" class=\"medical medical_review\">Large gastric folds: Hyperplastic and nonhyperplastic gastropathies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lymphocytic-and-collagenous-colitis-microscopic-colitis-clinical-manifestations-diagnosis-and-management\" class=\"medical medical_review\">Lymphocytic and collagenous colitis (microscopic colitis): Clinical manifestations, diagnosis, and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=malnutrition-in-children-in-resource-limited-countries-clinical-assessment\" class=\"medical medical_review\">Malnutrition in children in resource-limited countries: Clinical assessment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-patients-post-fontan-procedure\" class=\"medical medical_review\">Management of patients post-Fontan procedure</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mechanisms-of-nutrient-absorption-and-malabsorption\" class=\"medical medical_review\">Mechanisms of nutrient absorption and malabsorption</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nutrition-support-in-critically-ill-patients-an-overview\" class=\"medical medical_review\">Nutrition support in critically ill patients: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-heavy-proteinuria-and-the-nephrotic-syndrome\" class=\"medical medical_review\">Overview of heavy proteinuria and the nephrotic syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-clinical-manifestations-of-systemic-lupus-erythematosus-in-adults\" class=\"medical medical_review\">Overview of the clinical manifestations of systemic lupus erythematosus in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-treatment-of-malabsorption\" class=\"medical medical_review\">Overview of the treatment of malabsorption</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathophysiology-and-etiology-of-edema-in-adults\" class=\"medical medical_review\">Pathophysiology and etiology of edema in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sclerosing-mesenteritis\" class=\"medical medical_review\">Sclerosing mesenteritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tests-of-the-livers-biosynthetic-capacity-eg-albumin-coagulation-factors-prothrombin-time\" class=\"medical medical_review\">Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis</a></li></ul></div></div>","javascript":null}